Optain Health said it has acquired EyePACS, the nation’s largest teleophthalmology network, a move intended to expand access to retinal screening in primary-care settings. EyePACS has supported screening programs for more than 20 years across hundreds of clinics, identifying more than 140,000 patients with sight-threatening disease. The companies said their combined platform will focus on earlier detection of retinal and systemic conditions by pairing EyePACS’s established network with Optain’s automated imaging and artificial intelligence tools.

Optain’s technology includes a portable robotic retinal camera designed to capture high-quality images without dilation or trained operators. The company said this approach allows screenings to be performed in primary-care offices, community clinics, and home-health programs. EyePACS’s platform and workflows will continue to operate independently in the United States, while Optain invests in integrating the systems over time.

The acquisition also combines two longstanding research efforts. EyePACS has emphasized community-based screening and quality-improvement data, while Optain has advanced oculomics research focused on noninvasive detection of systemic disease through retinal imaging. Although Optain Health has announced deployments at 200 provider sites and partnerships with major health systems, the company’s robotic camera and AI-assisted image analysis software are not yet available for general sale in the United States. Current use in US clinics is limited to pilot programs and collaborative deployments with EyePACS, with broader commercial availability expected at a future date. RP